Delivra Health Brands (DHB) AI Stock Analysis

• Market Cap: C$4.53M
• Dividend Yield: N/A
• Average Volume (3M): 26.13K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.78
• Revenue Growth: 13.01%
• EPS Growth: -2445.45%
• Country: CA
• Employees: 22
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): -0.01
• Shares Outstanding: 31,261,782
• 10 Day Avg. Volume: 58,945
• 30 Day Avg. Volume: 26,134
• PEG Ratio: 0.02
• Price to Book (P/B): 1.30
• Price to Sales (P/S): 0.41
• P/FCF Ratio: -7.30
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: C$0.60
• Price Target Upside: 328.57% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): 0.01
• Revenue Forecast (FY): C$14.97M

• Rating: 43 Neutral
• Price Target: C$0.15 ▲(10.00% Upside)
• Action: Reiterated Date: 03/19/26
• Date: Action: Reiterated 03/19/26

The score is primarily held back by continued losses and inconsistent/negative cash flow, despite improved gross profitability and manageable leverage. Technical indicators also point to a continuing downtrend, and valuation is constrained by a negative P/E with no dividend support.

Positive Factors

Improved gross margins (~50%)

Sustained gross margins near 50% provide a durable profitability lever: healthy product-level margins can absorb input-cost variability, support operating leverage as fixed costs scale modestly, and materially shorten the path to positive operating cash flow as revenue growth resumes.

Manageable leverage and positive equity

Debt levels and a debt-to-equity ratio in the ~0.5–0.6 range imply conservative leverage for a small issuer. Positive equity provides a balance-sheet cushion, lowering refinancing risk and preserving optionality to fund growth initiatives or withstand short-term operational setbacks without immediate dilutive financing.

Multi-year revenue expansion (2021–2025)

Several years of top-line expansion signal market demand and commercial execution across retail and e‑commerce channels. This historical growth demonstrates addressable market traction and the potential to realize operating leverage and higher cash generation if the company can reaccelerate revenue.

Negative Factors

Ongoing unprofitability (TTM net margin ~-6%)

Persistent negative net margins and slightly negative EBIT indicate the turnaround is incomplete. Continued losses constrain retained earnings and reinvestment capacity, increase the likelihood of future equity dilution or external funding, and raise execution risk until operating profitability is consistently achieved.

Weak and volatile cash generation

Negative and erratic operating and free cash flow reduce financial flexibility and increase dependency on external capital. Volatility in cash generation complicates planning for marketing, inventory and distribution investments, and elevates the risk that growth initiatives will be underfunded without new financing.

Recent revenue momentum cooled (TTM -2.4%)

A slight TTM revenue decline after prior multi-year expansion signals potential demand plateau or execution headwinds. Slower top-line momentum limits the company's ability to convert healthy gross margins into operating profit and delays achievement of consistent positive free cash flow.

Delivra Health Brands Business Overview & Revenue Model

Company Description

Delivra Health Brands Inc. through its subsidiaries, provides lifestyle and wellness products to consumers and patients in regulated markets worldwide. The company is involved in selling of cannabis, liquid sleep shots, sleep powder packets, gummies, and pain relief creams. It offers its products under LivRelief, Dream Water, and LivRelief infused brand names. The company was formerly known as Harvest One Cannabis Inc. Delivra Health Brands Inc. is headquartered in Vancouver, Canada.

How the Company Makes Money

null

Delivra Health Brands Financial Statement Overview

Summary

Operationally improved versus 2021–2022 (gross margin ~50% and smaller losses), and leverage is manageable (debt-to-equity ~0.5–0.6). However, TTM revenue is slightly down (~-2.4%), the company remains unprofitable (TTM net margin ~-6%, EBIT slightly negative), and cash flow is weak/volatile with TTM and latest annual free cash flow negative.

Income Statement

Revenue expanded strongly from 2021–2025 annual, but the latest TTM (Trailing-Twelve-Months) shows a slight decline (about -2.4%), suggesting momentum has cooled. Profitability has improved materially versus 2021–2022 (when losses and margins were extremely weak), and gross margin is now healthy around ~50% in both 2025 annual and TTM. However, the company is still losing money (TTM net margin ~-6% and EBIT slightly negative), indicating the turnaround is incomplete and earnings remain sensitive to cost control and scale.

Balance Sheet

Leverage appears manageable, with debt around ~$2.1–$2.3M and debt-to-equity roughly ~0.5–0.6 in the most recent periods, which is not excessive for a small issuer. Equity remains positive, providing some balance sheet cushion. The key weakness is ongoing losses driving weak returns for shareholders (negative return on equity in all periods shown, including TTM), which can pressure equity over time if profitability does not improve.

Cash Flow

Cash generation is currently a concern: TTM (Trailing-Twelve-Months) operating cash flow and free cash flow are slightly negative (about -$0.1M), and the most recent annual period shows a much larger cash burn (about -$0.75M). While 2024 annual showed positive cash flow, the reversal back to negative in 2025 signals volatility and reduces financial flexibility. Overall, the business has not yet demonstrated consistent, repeatable free-cash-flow generation.

Breakdown	TTM	Sep 2025	Sep 2023	Sep 2022	Sep 2021	Sep 2020
Income Statement
Total Revenue	13.09M	13.37M	12.38M	9.79M	8.14M	7.96M
Gross Profit	6.36M	6.78M	6.40M	3.49M	485.00K	-297.00K
EBITDA	307.00K	427.00K	2.35M	1.40M	-4.25M	-7.04M
Net Income	-405.00K	-1.19M	876.00K	-184.00K	-7.01M	-28.54M
Balance Sheet
Total Assets	8.04M	9.61M	10.05M	10.56M	11.59M	19.06M
Cash, Cash Equivalents and Short-Term Investments	3.23M	3.30M	4.20M	2.73M	1.11M	5.14M
Total Debt	2.26M	2.11M	2.03M	1.96M	2.11M	2.16M
Total Liabilities	4.25M	5.37M	4.86M	7.17M	8.21M	9.09M
Stockholders Equity	3.80M	4.24M	5.19M	3.39M	3.37M	9.98M
Cash Flow
Free Cash Flow	-111.00K	-754.00K	756.00K	-1.13M	-4.46M	-9.68M
Operating Cash Flow	-111.00K	-754.00K	756.00K	-1.09M	-4.44M	-9.65M
Investing Cash Flow	0.00	0.00	11.00K	2.91M	1.35M	12.27M
Financing Cash Flow	-20.00K	-36.00K	594.00K	-255.00K	-309.00K	446.00K

Delivra Health Brands Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.14
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:DHB, the sentiment is Negative. The current price of 0.14 is below the 20-day moving average (MA) of 0.17, below the 50-day MA of 0.18, and below the 200-day MA of 0.22, indicating a bearish trend. The MACD of -0.01 indicates Positive momentum. The RSI at 39.58 is Neutral, neither overbought nor oversold. The STOCH value of 10.26 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:DHB.

Delivra Health Brands Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
PCLO	50 Neutral	C$9.23M	5.19	―	―	15.64%	58.47%
TGIF	44 Neutral	C$4.96M	13.38	―	―	-2.30%	―
DHB	43 Neutral	C$4.53M	-3.90	-9.77%	―	13.01%	-2445.45%
CDVA	43 Neutral	C$2.75M	-6.37	50.26%	―	1.60%	-213.10%

Delivra Health Brands Corporate Events

Delivra Health Unveils Dream Water Kids Sleep Gummies and Grants New Stock Options

Delivra Health Brands is expanding its Dream Water portfolio with the launch of Dream Water Kids Sleep Gummies in the U.S. market, expected to reach distributors, retailers, and online channels in June 2026. The kid-focused gummies, formulated with chamomile, lemon balm, and a low dose of melatonin, aim to offer parents a gentle, convenient sleep support option for children, reflecting the company’s emphasis on product innovation and growing demand for family-oriented wellness solutions.

Alongside the product launch, Delivra Health granted 815,000 stock options to directors, officers, employees, and consultants at an exercise price of $0.16 per share, vesting over three years. The options, issued under the company’s fixed stock option plan, underscore efforts to align incentives with long-term performance as the company seeks to strengthen its position in the competitive health and wellness market.

The most recent analyst rating on (TSE:DHB) stock is a Sell with a C$0.15 price target. To see the full list of analyst forecasts on Delivra Health Brands stock, see the TSE:DHB Stock Forecast page.

Delivra Health Q2 Revenue Slips as E-Commerce Growth Offsets Retail Weakness

Delivra Health reported weaker second-quarter fiscal 2026 results as net revenue fell 12% to $2.4 million, driven by lower Dream Water sales in the U.S. and Canada, reduced LivRelief retail and infused cream volumes, and a shift in distribution channels. Despite the revenue decline and a drop in gross margin to 40%, the company is seeing strong year-to-date e-commerce growth of 26% for Dream Water and 28% for LivRelief, while cutting expenses, and management is prioritizing stabilizing retail ordering patterns, optimizing channels and expanding high-margin direct-to-consumer and U.S. opportunities to restore consistent revenue growth.

The most recent analyst rating on (TSE:DHB) stock is a Hold with a C$0.17 price target. To see the full list of analyst forecasts on Delivra Health Brands stock, see the TSE:DHB Stock Forecast page.

Delivra Health Brands Adds Veteran CPG Executive John Barrett to Board

Delivra Health Brands has appointed John Barrett, a veteran consumer goods executive with senior leadership experience at Frito Lay, PepsiCo and Pernod Ricard, to its board of directors, replacing outgoing director Andrew Bayfield. Currently head of boutique consultancy Kites Advisors, Barrett brings extensive North American and international expertise in innovation, marketing, commercial strategy, major customer acquisition and profit-and-loss management, which the company’s executive chair says will be key as Delivra pursues its next phase of growth and seeks to strengthen execution of its strategic priorities and long-term value creation, subject to TSX Venture Exchange approval.

The most recent analyst rating on (TSE:DHB) stock is a Hold with a C$0.21 price target. To see the full list of analyst forecasts on Delivra Health Brands stock, see the TSE:DHB Stock Forecast page.